About Merck
Merck is a publicly listed company based in Kenilworth (United Kingdom) founded in 1891. Pharmaceutical products are manufactured and marketed worldwide. It operates on a Direct-to-Consumer (D2C) and Professional Services model. The company has 781 employees. Merck has completed 33 acquisitions, including Abceutics, Acceleron Pharma and Afferent Pharmaceuticals. Its chief executive, as recorded, is Robert M Davis. Its website merck.com draws about 657 thousand monthly visits. Merck offers products and services including Medicines and Vaccines and Animal Health Products. Its focus areas include Pharmaceuticals, Biopharmaceuticals, Animal Health and Veterinary Products. Its legal entity is Merck & Co., Inc.
Company details
Merck is established as a premier biopharmaceutical company focused on research and development. The company is engaged in creating innovative medicines and vaccines across various therapeutic areas including oncology, infectious diseases, and cardio-metabolic disorders. Solutions are developed through advanced data science, artificial intelligence, and sustainable science practices. Operations are conducted with a commitment to sustainability, aiming to benefit global communities. The animal health division is also managed, providing products for veterinary care worldwide.
- Annual Revenue$64.93 B (USD)1.49as on Dec 31, 2025
- Net Profit$18.25 B (USD)6.64as on Dec 31, 2025
- EBITDA$29.32 B (USD)16.63as on Dec 31, 2025
- Latest Funding Round$167K (USD), Grant
Sep 2021
- InvestorsGates Foundation
& 2 more
- Employee Count781
- Investments & AcquisitionsAbceutics
& 32 more
Products & Services of Merck
Merck offers a comprehensive portfolio of products and services, including Medicines and Vaccines and Animal Health Products.
Medicines and vaccines are developed for various diseases.
Products for animal health are provided globally by Merck.
Funding Insights of Merck
- Total Rounds 11
- Last Round Grant — $167,000
- First Round $150,153
(Apr 2011)
- Investors Count 3
Latest 10 of 11 funding rounds of Merck with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2021 | $167,000 | Grant | – | – | |
| Nov 2018 | $288,246 | Grant | – | – | |
| Oct 2018 | $292,652 | Grant | – | – | |
| Dec 2017 | $62,704 | Grant | – | – | |
| Jan 2017 | $1.72M | Grant | – | – | |
| Oct 2016 | $1.09B | Debt – Conventional | – | – | – |
| May 2016 | $285,637 | Grant | – | – | |
| Feb 2016 | $546,250 | Grant | – | – | |
| Mar 2015 | $1.94M | Grant | – | – | |
| Jun 2013 | Post-IPO | – | – |
3 investors in total: 3 institutional.
Investors in Merck
Merck has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Gates Foundation, HHS and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Charitable foundation investments on poverty reduction and healthcare | 2000 | gatesfoundation.org | Seattle, United States |
Investor details for Merck
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Merck
1248 people are tracked at Merck (845 in leadership, 12 in board & advisors, 391 in team); the tracked headcount is 781.
| Name | Role | Group |
|---|---|---|
Robert M Davis | CEO | Leadership |
Jacob Bordens | Senior Director, Enterprise Architecture | Leadership |
Kelley Brna | Vice President Operations | Leadership |
Robert Tynebor | Director | Leadership |
Jerry Timmons | Retired Associate Director Of Operations | Leadership |
Sebastian S. | Director | Leadership |
Dave Williams | EVP, Chief Information & Digital Officer | Leadership |
Hardik Chandasana | Director, Quantitative Pharmacology And Pharmacometrics | Leadership |
My Mansueto | Director | Leadership |
Edina Avdic | Associate Director-regulatory Affairs-global Labeling | Leadership |
Manshi Patel | Associate Director- Global Microbial Quality Sterility Assurance | Leadership |
Sany Hoxha | Director, Oncology Translational Science And Clinical Biomarkers | Leadership |
Ashley Wivel | Vice President, Head Of Clinical Safety And Risk Management | Leadership |
Naveed Shaik | Director, Quantitative Pharmacology And Pharmacometrics | Leadership |
Allison Shaner | Chief Of Staff, HR Manufacturing | Leadership |
Brandon Koffel | Associate Director Discovery Sourcing & Procurement - Global Clinical Supply & Analytical Labs | Leadership |
Andrea Lorena Buitrago Lozano | Associate Director, Lead Study Manager | Leadership |
Aatosh Chauhan | Executive Director, External Manufacturing Strategy & Operations At Merck | Leadership |
Renata Eiras | Executive Director, Distinguished Scientist, PDT Lead | Leadership |
Gina M. Gualtiere Mshs | Associate Director Clinical Quality Operations | Leadership |
1228 more people are available in the full profile.
Complete people profiles for Merck
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Merck
Merck is a publicly listed company on the NYSE with ticker symbol MRK in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date01 Jan 1941
- Listed onNYSE: MRK
- Listed entityMerck & Company, Inc.
- Exchange sectorHealth technology
- ISINUS58933Y1055
- Share price$141.98 (-2.39% on the day) · 2026-10-13
- Market capitalisation$350.29B
- Price to earnings113.5
- EPS (diluted, trailing year)$1.25
- Dividend yield2.39%
- Volume (last session)8,379,646
Financials of Merck
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $64.93B | $18.25B | $29.32B |
| 2024 | $63.97B | $17.12B | $25.14B |
| 2023 | $59.87B | $365.0M | $6.85B |
| 2022 | $58.47B | $14.52B | $23.41B |
| 2021 | $48.91B | $13.05B | $18.83B |
Detailed financial statements for Merck
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Merck
Merck has strategically engaged in corporate development activities, having acquired 33 companies. Notable acquisitions include Abceutics, Acceleron Pharma and Afferent Pharmaceuticals.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Therapies for liver disease and cancer are developed. | ternspharma.com | San Mateo, United States | 2017 | Mar 2026 | $6.7B | |
Novel anti-infectives for bacterial and fungal infections are developed. | cidara.com | San Diego, United States | 2013 | Nov 2025 | •••• | |
Respiratory disease drugs for asthma and COPD are developed. | veronapharma.com | London, United Kingdom | 2005 | Jul 2025 | $10B | |
Developer of therapeutics for the treatment of cancer | modifibio.com | New Haven, United States | 2021 | Oct 2024 | $30M | |
Antibody-drug conjugates for cancer treatment are enhanced by Abceutics. | abceuticsinc.com | Buffalo, United States | 2020 | Apr 2024 | •••• | |
Neurodegenerative disease treatments are developed using stem cell-derived neurons. | carawaytx.com | Cambridge, United States | 2018 | Nov 2023 | •••• | |
Drugs for gastrointestinal diseases are developed using clinical biobanks. | prometheusbiosciences.com | San Diego, United States | 2016 | Apr 2023 | $10.8B | |
Developer of epigenetic-based therapies for rare genetic cancers | imagobio.com | San Francisco, United States | 2012 | Nov 2022 | $1.35B | |
Protein therapeutics are developed for cancer and rare blood disorders. | acceleronpharma.com | Cambridge, United States | 2004 | Sep 2021 | $11.5B | |
Therapeutic solutions via localized immunomodulation are developed. | pandiontx.com | Watertown, United States | 2017 | Feb 2021 | $1.9B |
Complete acquisition details for Merck
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Merck
14 dated milestones of Merck across 135 years, from founding to its latest funding, stage changes and deals.
- Founded Merck is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $150K.
- Acquisition Acquires Pandion Therapeutics.
- Funding Latest funding round, Grant, of $167K.
- Acquisition Acquires Acceleron Pharma.
- Acquisition Acquires Imago BioSciences.
- Acquisition Acquires Prometheus Biosciences.
- Acquisition Acquires Caraway Therapeutics.
- Acquisition Acquires Abceutics.
- Acquisition Acquires Modifi Bio.
- Acquisition Acquires Verona Pharma.
- Acquisition Acquires Cidara Therapeutics.
- Acquisition Acquires Terns Pharmaceutical.
Web traffic of Merck
The website of Merck (merck.com) receives about 656.8K visits a month and ranks #78,842 among all websites worldwide, #2,235 in Biotechnology and Pharmaceuticals.
- Monthly visits656.8K
▲ 9.7% vs previous month
- Unique visitors245.9K
per month
- Global rank#78,842
among all websites
- Category rank#2,235
Health · Biotechnology and Pharmaceuticals
- Bounce rate48%
- Pages per visit3.4
- Average visit2 min 32 sec
- DevicesDesktop 61% · Mobile 39%
Websites whose visitors overlap most with Merck. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| pfizer.com | 100% | 1.9M | #24,984 | View details | |
| novartis.com | 95% | 948.8K | #58,822 | View details | |
| astrazeneca.com | 90% | 1.3M | #48,983 | View details | |
| merckgroup.com | 88% | 910.8K | #54,804 | View details | |
careers.lilly.com | careers.lilly.com | 76% | #60,411 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Merck
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Merck
Complete news archive for Merck
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Merck
Merck was founded in 1891 and raised its 1st funding round 120 years after it was founded.
Merck is headquartered in Kenilworth, United Kingdom. It is registered at Kenilworth, Warwickshire, United Kingdom.
Robert M Davis is the CEO of Merck, as recorded in our data.
Merck has 781 employees.
Annual revenue of Merck is $64.93B as on Dec 31, 2025.
Merck is established as a premier biopharmaceutical company focused on research and development. The company is engaged in creating innovative medicines and vaccines across various therapeutic areas including oncology, infectious diseases, and cardio-metabolic disorders. Solutions are developed through advanced data science, artificial intelligence, and sustainable science practices. Operations are conducted with a commitment to sustainability, aiming to benefit global communities. The animal health division is also managed, providing products for veterinary care worldwide.
Merck offers Medicines and Vaccines and Animal Health Products.
Yes, Merck is publicly traded on NYSE under the ticker symbol MRK.
Merck has made 33 acquisitions, including Abceutics, Acceleron Pharma, and Afferent Pharmaceuticals.
Merck has 3 investors. Key investors include Gates Foundation, HHS, and European Union.
Merck operates through Merck & Co., Inc..
The website of Merck receives about 657 thousand visits a month and ranks #78,842 among all websites worldwide.